

## C73 RESIDUAL SOLVENTS IN HEMP OIL

### 1.0 Sample Reception

- 1.1 This PT is provided as four different spiking solution, C73-1a, C73-1b, C73-2a and C73-2b. C73-1a and C73-2a contain the butanes and propanes in N,N-Dimethylacetamide. The other two ampoules contain the other analytes in Glyceryl Triacetate. In addition to these flame sealed ampoules, approximately 5 g of volatile free hemp oil is provided as the base matrix to receive the spikes.
- 1.2 Upon receipt samples are to be checked for deficiencies. The flame sealed ampoules containing the spiking concentrates should be stored at freezer temperatures, the Base Oil Matrix can be stored at room temperature.
- 1.3 Inquiries regarding samples and their shipment may be directed to:

**Phenova**

Tel: (866) 942-2978

Email: TyG@phenova.com

**PT Canada**

Tel: (613) 233-5464

Email: programadmin@ptcanada.org

Email: kmiddlebrook@ptcanada.org

Inquiries must be made by email only. Use the enclosed Nonconformance Form (see reverse) when notifying PT Canada of a problem with the samples. Please include your PT Canada laboratory number on all correspondence.

### 2.0 General Information

- 2.1 Due to the volatile nature of propane and butanes (C73-1a and C73-2a), please limit the time the ampoule is open to air and warm temperatures prior to use. Once the ampoule is cracked, it is suggested that the spiking solution be immediately transferred to an appropriate gastight storage vial and stored at freezer temperatures for potential future use.
- 2.2 The solvent matrix for the other target analytes is Glyceryl Triacetate. Glyceryl Triacetate is a relatively viscous solvent and is best handled at room temperature. Care should be taken when an aliquot is removed using a gastight syringe to ensure accuracy of measurement. Once the ampoule is cracked, it is suggested that the spiking solution be immediately transferred to an appropriate gastight storage vial and stored at freezer temperatures for potential future use.
- 2.3 It is suggested that the Propane/Butanes spike be performed and analyzed separately from the Glyceryl Triacetate spiking solution containing the other target analytes. N,N-Dimethylacetamide can interfere with the analysis of other target analytes existing in the Triacetin spike solution.

### 3.0 Sample Preparation

- 3.1 Warm the flame sealed ampoules to room temperature.
- 3.2 Open the hemp oil vial and weigh out 20.0 milligrams of the oil base matrix into four headspace vials.
- 3.3 Carefully open the flame sealed ampoule labeled C73-1a, and using a gastight syringe, spike exactly 5uL of the spiking solution onto the 20.0 milligram oil matrix in one of the headspace vials and immediately cap/seal the vial. Repeat this process for C73-1b, C73-2a and C73-2b, using a different hemp oil containing headspace vial for each.
- 3.4 The samples are now ready to analyze as per your normal procedures. It is suggested the sample be immediately included in an analytical run after spiking.

### 4.0 Sample Analysis

- 4.1 Potential concentrations of the reportable analytes, if the analyte is included, are estimated

between 500 and 7000 µg/g.

- 4.2 Proceed with testing using your routine analytical method.

## 5.0 Reporting Results

- 5.1 For this PT assume 0% moisture, no dry weight adjustment is necessary when reporting results.
- 5.2 Results must be reported by midnight of the study deadline using the PT Canada web-data-entry system.
- 5.3 Results are to be reported as µg/g.
- 5.4 If the analyte is non-detect, please report it as <### (e.g., <100).

## 5.0 Safety

- 5.1 The PT samples are designed for use by laboratory professionals familiar with cannabis samples and potentially hazardous materials.

# PT SAMPLE NON-CONFORMANCE FORM

Attn: PT non-conformances

Study Number:

ENSURE THAT SAMPLES RECEIVED MATCH REPORT FORMS

## 1 - Laboratory Information

Contact Name:

Laboratory Name

Laboratory Address

Contact Telephone #

Contact Facsimile #

Contact e-mail:

## 2 - Sample Details

Date & Time of Arrival(YYYY,MM,DD,HH:MM):

Tracking Number:

Test Groups Received (e.g. C1, C2 etc.):

Number of Boxes:

## 3 - Description of Nonconformance

## 4 - Requested Action

## 5 - PT Provider Notes